Inside Wall Street's Fringes: CXApp's Survival Bid and Summit's Data ScrutinyGlobal Report·Aug 19 at 05:12 AMCXAI-0.64%SMMT+4.63%
Moleculin: Buy Rating Maintained as MIRACLE Trial Progress Offsets Dilution; McCarthy Trims Price Target After Equity FinancingTip Ranks·Aug 15 at 09:05 AMMBRX+4.22%
Moleculin Biotech reports Q2 2026 loss of $7.6M, cash $7.3M; MIRACLE trial interim efficacy positiveTradingView·Aug 14 at 07:33 AMMBRX+4.22%
Moleculin Biotech reports interim MIRACLE trial data showing higher remission rates in relapsed/refractory AMLPUBT·Aug 14 at 07:32 AMMBRX+4.22%
Moleculin net loss narrows to $7.64 million in Q2 FY26; R&D expense rises to $5.45 millionPUBT·Aug 13 at 03:28 PMMBRX+4.22%
The Market's Barbell Reality: From Copper Veins to Drone OpportunitiesGlobal Report·Aug 11 at 05:13 AMMFC-0.28%REA+0.98%
Moleculin Biotech Chief Science Officer Donald H. Picker acquires common shares worth $129,999.75PUBT·Aug 5 at 03:17 PMMBRX+4.22%
Pre-market hot trades in US stocks: ON Semiconductor up 7.34% in pre-market; Moleculin Biotech down 6.40% in pre-marketPrice Alert·Aug 4 at 04:38 AMON-0.17%MBRX+4.22%
Micro-Cap Reality Check: Software Nabs Mega-Contracts While Gig and Energy Firms Face DelistingsGlobal Report·Aug 4 at 04:17 AMQTWO-1.95%WYY+0.44%
U.S. stock night market opening fluctuations: Moleculin Biotech fell 3.53% in the night market; Replimune fell 3.19% in the night marketPrice Alert·Aug 3 at 07:17 PMMBRX+4.22%REPL+5.27%
Moleculin reports interim results from MIRACLE trial in r/r AML patientsWorldPharmaceuticals·Aug 3 at 05:14 AMMBRX+4.22%
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga_article·Jul 31 at 12:05 PMMBRX+4.22%NUWE-4.76%
